No Data
No Data
Should You Buy the Dip on Compass Pathways Stock?
Morgan Stanley Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Cuts Target Price to $23
Morgan Stanley analyst Vikram Purohit maintains $COMPASS Pathways(CMPS.US)$ with a buy rating, and adjusts the target price from $30 to $23.According to TipRanks data, the analyst has a success rate o
Psychedelic Drug Stocks Plummet On FDA Advisers' Doubts About Ecstasy Candidate -- WSJ
By Liz Essley Whyte Stocks for companies developing psychedelic treatments fell Wednesday after advisers to the Food and Drug Administration voted against a mental-health therapy using the drug MDMA,
What's Going On With MindMed And Psychedelic Stocks?
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) shares are trading lower Wednesday after a Food and Drug Administration (FDA) panel rejected the approval of MDMA therapy for people with post-traumatic stre
Morgan Stanley Adjusts COMPASS Pathways Price Target to $23 From $30, Maintains Overweight Rating
COMPASS Pathways (CMPS) has an average rating of Buy and price targets ranging from $22 to $120, according to analysts polled by Capital IQ. Price: 6.59, Change: -1.08, Percent Change: -14.08
FDA advisory group refuses MDMA marketing authorization; psychedelic concept stocks slump.
The independent advisory group of the US FDA voted against the marketing authorization application for the psychiatric drug MDMA, causing a pre-market drop for the hallucinogenic drug developer.
No Data